Stifel Financial Corporation reported earnings for the fourth quarter of 2024, significantly surpassing analyst expectations.
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.
James reaffirmed its Outperform rating on Colgate-Palmolive Company (NYSE:CL), a $70.3 billion consumer goods giant with ...